Related Experiment Video
Updated: Jun 19, 2025
14:57
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
14.4K
Glutathione dynamics in subcellular compartments and implications for drug development.
Hanfeng Lin1, Lingfei Wang2, Xiqian Jiang3
1Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX 77030, USA; Center for NextGen Therapeutics, Baylor College of Medicine, Houston, TX 77030, USA.
Current Opinion in Chemical Biology
|July 25, 2024
Summary
Glutathione (GSH), a key antioxidant, plays vital roles in cellular health across different organelles. Understanding its subcellular dynamics is crucial for developing new drugs and cancer therapies.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Glutathione (GSH) is a critical tripeptide antioxidant maintaining cellular redox balance.
- GSH's functions are diverse and compartmentalized across cellular organelles like the cytosol, mitochondria, ER, and nucleus.
- Dysregulation of GSH dynamics is linked to various pathophysiological conditions.
Purpose of the Study:
- To review and consolidate current knowledge on subcellular glutathione dynamics.
- To highlight the implications of GSH dynamics in drug development, including covalent drug design and antitumor strategies.
- To discuss challenges and future directions in studying and modulating subcellular GSH.
Main Methods:
- Literature review and synthesis of existing research on glutathione.
- Analysis of GSH's role in different subcellular compartments.
- Exploration of therapeutic strategies targeting GSH levels.
Main Results:
- GSH exhibits distinct regulatory mechanisms in various cellular compartments.
- Subcellular GSH levels are critical targets for drug development.
- Modulating intracellular GSH holds promise for antitumor therapies.
Conclusions:
- A comprehensive understanding of subcellular GSH dynamics is essential for advancing therapeutic interventions.
- Innovative methodologies are needed to further elucidate GSH regulation.
- Targeting GSH offers potential for precise drug design and cancer treatment.
More Related Videos
Related Concept Videos
01:22Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
176
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
176
01:16Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
01:14Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
01:21Drug Distribution: Tissue Binding
2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
2.6K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
36
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
36
01:06Carrier-Mediated Transport
322
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
322